Re-ablation of Persistent Atrial Fibrillation

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAarhus University Hospital

About this trial

Pulmonary vein re-isolation plus Vein of Marshall ethanol ablation in combination with block of mitral and tricuspid isthmuses and dome line will be compared to pulmonary vein re-isolation alone in patients undergoing re-ablation for persistent atrial fibrillation in this investigator initiated, randomized, patient-assessor blinded multicenter trial. Patients are followed with standard ECG at 3 months, with standard ECG, 5-days' ECG monitoring and quality of life assessment after 12 months, with standard ECG and quality of life assessment after 24 months, through patient files at 60 months after the ablation.

Primary endpoint: Change in AFEQT score between baseline and 12 months.

Eligibility criteria

Qualifiers

Previous pulmonary vein isolation for atrial fibrillation

Indication for catheter ablation with at least two episodes of symptomatic PsAF during the last 12 months

Age > 18 years

Expected survival > 12 months

Disqualifiers

Previous extrapulmonary atrial ablation other than cavotricuspid isthmus line, roof- or dome line or posterior wall isolation/ablation

Atypical atrial flutter in addition to atrial fibrillation

Atrial fibrillation secondary to a transient abnormality

Uncontrolled hypertension

Trial design

Treatments tested in this trial

  • Intervention
  • Control

Treatment groups

180 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Aarhus University Hospital

Lead sponsor

Karolinska University Hospital

Collaborator

Leiden University Medical Center

Collaborator